Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 6, 2026, 3:56 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 961–984 of 7,258 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: High-Risk Clear all

Conditions: Sarcoma
Interventions: filgrastim, busulfan, melphalan, thiotepa, peripheral blood stem cell transplantation, radiation therapy; Biological · Drug · Procedure + 1 more
Lead sponsor: Fred Hutchinson Cancer Center; Other
Eligibility: Up to 49 Years
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1998 – 2002
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Dyslipidemias, High Cholesterol, Hypercholesterolemia, Familial Hypercholesterolemia, Lipid Metabolism Disorder, Metabolic Disease, Lipid Metabolism, Inborn Errors, Genetic Disease, Inborn, Hyperlipoproteinemias
Interventions: Obicetrapib, Placebo; Drug
Lead sponsor: NewAmsterdam Pharma; Industry
Eligibility: 18 Years and older
Enrollment: 354 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 20
States / cities: Jonesboro, Arkansas • Toluca Lake, California • Sarasota, Florida + 17 more

Conditions: Periampullary Neoplasms, Pancreatic Cancer, Pancreatic Neoplasms
Interventions: Total Pancreatectomy with Islet Autotransplantation (TPIAT); Procedure
Lead sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2031
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Metastatic Skin Squamous Cell Carcinoma, Recurrent Skin Squamous Cell Carcinoma
Interventions: Cemiplimab, Radiation Therapy, Therapeutic Conventional Surgery; Biological · Radiation · Procedure
Lead sponsor: Emory University; Other
Eligibility: 18 Years and older
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2031
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Lymphoma, Non-Hodgkin
Interventions: Recombinant Human Interleukin-2 and Rituximab; Drug
Lead sponsor: Chiron Corporation; Industry
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 33
States / cities: Tucson, Arizona • Newport Beach, California • Sacramento, California + 28 more

Conditions: Neuroblastoma
Interventions: Protracted Oral Etoposide, Doxorubicin, IV Bolus Etoposide, Cisplatin, Cyclophosphamide, Mesna, Hematopoietic Factor, Primary tumor resection; Drug · Procedure
Lead sponsor: Baylor College of Medicine; Other
Eligibility: Not listed
Enrollment: 13 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2015
U.S. locations: 1
States / cities: Houston, Texas

Conditions: ASCVD
Interventions: Pharmacist call; Other
Lead sponsor: Duke University; Other
Eligibility: 18 Years to 75 Years
Enrollment: 225 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025
U.S. locations: 2
States / cities: Wilmington, Delaware • Durham, North Carolina

Conditions: Hypertension
Interventions: Best Practice Clinic-Based Care, Telehealth Care; Other
Lead sponsor: HealthPartners Institute; Other
Eligibility: 18 Years to 85 Years
Enrollment: 3,071 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2021
U.S. locations: 1
States / cities: Bloomington, Minnesota

Conditions: Child Behavior
Interventions: KEEP-P+; Behavioral
Lead sponsor: University of Oregon; Other
Eligibility: 30 Months to 6 Years
Enrollment: 442 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2018
U.S. locations: 1
States / cities: Eugene, Oregon

Conditions: High-risk, Non-cardiovascular Surgeries
Interventions: Esmolol; Drug
Lead sponsor: Duke University; Other
Eligibility: 41 Years and older
Enrollment: 76 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2013
U.S. locations: 3
States / cities: Durham, North Carolina • Columbus, Ohio

Conditions: Respiratory Syncytial Virus (RSV)
Interventions: RSVpreF, Placebo; Biological
Lead sponsor: Pfizer; Industry
Eligibility: 5 Years to 17 Years
Enrollment: 920 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2031
U.S. locations: 5
States / cities: Durham, North Carolina • Cincinnati, Ohio • South Euclid, Ohio + 1 more

Conditions: Healthy
Interventions: Bazedoxifene/conjugated estrogens combination; Drug
Lead sponsor: Wyeth is now a wholly owned subsidiary of Pfizer; Industry
Eligibility: 35 Years to 70 Years · Female only
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007
U.S. locations: 1
States / cities: Gainesville, Florida

Conditions: Diabetic Macular Edema
Interventions: Macugen (Pegaptanib Sodium); Drug
Lead sponsor: Retina Institute of Hawaii; Other
Eligibility: 18 Years and older
U.S. locations: 1
States / cities: Honolulu, Hawaii

Conditions: Stroke, Stroke Rehabilitation, Lower Extremity Weakness, Spastic, Walking, Difficulty
Interventions: High Intensity Interval Training (HIIT); Other
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 18 Years to 89 Years
Enrollment: 55 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: Decatur, Georgia

Conditions: Post-Menopausal, Breast Cancer
Interventions: Letrozole; Drug
Lead sponsor: Dana-Farber Cancer Institute; Other
Eligibility: 18 Years and older · Female only
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2005
U.S. locations: 3
States / cities: Boston, Massachusetts

Conditions: Lung Cancer
Interventions: Portal Message with Reminder Text Messages, Text Message with Reminder Text Messages, Portal message only, Usual Care; Other
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: 50 Years to 77 Years
Enrollment: 27,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Winston-Salem, North Carolina

Conditions: Large B-cell Lymphoma, High-grade B-cell Lymphoma, Transformed B-Cell Lymphoma, Follicular Lymphoma Grade 3B
Interventions: Mosunetuzumab, DHAX, ICE; Drug
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years and older
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2029
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Ovarian Cancer, Epithelial, Peritoneal Cancer, Fallopian Tube Cancer
Interventions: Streamlined Education, Traditional Education; Behavioral
Lead sponsor: Duke University; Other
Eligibility: 18 Years and older · Female only
Enrollment: 64 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Anal Neoplasm
Interventions: VGX-3100, CELLECTRA™ 5PSP; Biological · Device
Lead sponsor: Inovio Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 23 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 2
States / cities: Chicago, Illinois • New York, New York

Conditions: Melanoma
Interventions: Pembrolizumab/Vibostolimab, Pembrolizumab; Biological
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 12 Years and older
Enrollment: 1,594 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 30
States / cities: La Jolla, California • Los Angeles, California • San Francisco, California + 22 more

Conditions: Blood And Marrow Transplantation, Leukemia, Lymphoma, Transplantation Infection, Transplantation, Bone Marrow
Interventions: Melphalan, Fludarabine, Mycophenolate mofetil, Tacrolimus, Cord Blood Infusion, Rituximab, ATG, Busulfan, Clofarabine, Total Body Irradiation (TBI); Drug · Procedure · Radiation
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 1 Year to 80 Years
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2017
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Myelodysplastic Syndrome, Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Chronic Myelomonocytic Leukemia
Interventions: Clofarabine; Drug
Lead sponsor: UNC Lineberger Comprehensive Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 13 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2013
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Neuromyelitis Optica
Interventions: High Frequency Impulse Therapy, High Frequency Impulse Therapy - Sham; Device
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years and older
Enrollment: 46 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: High Grade Anal Canal Squamous Intraepithelial Neoplasia, HIV Infection
Interventions: Concept Elicitation, Comprehension Assessment; Other
Lead sponsor: AIDS Malignancy Consortium; Network
Eligibility: 35 Years and older
Enrollment: 85 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 6
States / cities: San Francisco, California • Chicago, Illinois • New York, New York + 1 more

Search by objective public record fields.

Combination Chemotherapy, Peripheral Stem Cell Transplantation, and Radiation Therapy in Treating Patients With Ewing's Sarcoma, Peripheral Primitive Neuroectodermal Tumor, or Rhabdomyosarcoma

Evaluate the Effect of Obicetrapib in Patients With HeFH on Top of Maximum Tolerated Lipid-Modifying Therapies.

Total Pancreatectomy With Islet Autotransplantation (TPIAT) for High-Risk Patients With Pancreatic Tumors

Cemiplimab Before and After Surgery for the Treatment of High Risk Cutaneous Squamous Cell Cancer

Proleukin in Combination With Rituxan in Patients With Intermediate and High-Grade Non-Hodgkin's Lymphoma.

Protracted Etoposide During Induction Therapy for High Risk Neuroblastoma

ACHIEVE Pilot Statins for Vascular Protection

Pragmatic Trial Comparing Telehealth Care and Optimized Clinic-Based Care for Uncontrolled High Blood Pressure

Trial of KEEP-P, a Preventive Intervention for Foster Preschoolers (KEEP-P)

Esmolol for Treatment of Perioperative Tachycardia

Study to Learn About a Respiratory Syncytial Virus Vaccine in Children at High Risk of RSV Disease

Study Evaluating Bazedoxifene/Conjugated Estrogens Combinations in Fed and Fasting in Healthy, Postmenopausal Women

A Single-Center Trial of High Frequency Pegaptanib for Rapid Restoration of VEGF Levels in Diabetic Retinal Edema

Biomarkers of Reaction To HIIT Exercise

Letrozole in Postmenopausal Women at Increased Risk for Breast Cancer

A Mobile Patient Health Technology Intervention for Improving Lung Cancer Screening Rates in Eligible High Risk Patients

Mosunetuzumab in Combination With Platinum-Based Salvage Chemotherapy in Patients With Relapsed/Refractory Aggressive B Cell Lymphoma

Prospective Randomized Trial of Streamlined Genetic Education and Testing for Ovarian Cancer Patients

VGX-3100 Delivered Intramuscularly (IM) Followed by Electroporation (EP) for the Treatment of HPV-16 and/or HPV-18 Related Anal or Anal/Peri-Anal, High Grade Squamous Intraepithelial Lesion (HSIL) in Individuals Seronegative for Human Immunodeficiency Virus (HIV)-1/2

A Study of Adjuvant Pembrolizumab/Vibostolimab (MK-7684A) Versus Pembrolizumab for Resected High-Risk Melanoma in Participants With High-Risk Stage II-IV Melanoma (MK-7684A-010/KEYVIBE-010)

Cord Blood Fucosylation to Enhance Homing and Engraftment in Patients With Hematologic Malignancies

PK Study of Oral and IV Clofarabine in High Risk Myelodysplasia+Acute Leukemias

High Frequency Impulse Therapy for Neuropathic Pain in NMOSD

Health-Related Symptom Questionnaires in Measuring Quality of Life in HIV-Infected Participants Treated or Monitored for Anal Lesions